Champions Oncology (CSBR) Equity Average (2011 - 2026)

Champions Oncology's Equity Average history runs 16 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Equity Average rose 38.44% year-over-year to $4.3 million; the TTM figure through Jan 2026 stood at $4.3 million (up 38.44% YoY), while the FY2025 annual figure was $934500.0, down 31.61% from the prior year.
• Equity Average was $4.3 million for Q1 2026 at Champions Oncology, up from $3.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $9.2 million in Q2 2022 to a low of -$2.0 million in Q2 2024.
• Historically, Equity Average has averaged $4.1 million across 5 years, with a median of $3.9 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Equity Average tumbled 134.18% in 2024, then soared 2126.07% in 2025.
• A 5-year view of Equity Average shows it stood at $9.1 million in 2022, then slumped by 89.01% to $998000.0 in 2023, then tumbled by 82.52% to $174500.0 in 2024, then jumped by 2126.07% to $3.9 million in 2025, then increased by 9.59% to $4.3 million in 2026.
• The last three Equity Average figures came in at $4.3 million (Q1 2026), $3.9 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.